Methamphetamine, PrEP, and Intersectional Stigma Study
NCT05784467
Acquired Immunodeficiency Syndrome, Behavior
View Trial DetailsNCT Number: NCT07309757
The purpose of this study is to develop a pilot screening protocol, comparing cardiac point-of-care ultrasound (POCUS), electrocardiogram (EKG), serum biomarkers (N-terminal pro b-type natriuretic peptide (NT-proBNP), high sensitivity troponin (hsTn)) with formal transthoracic echocardiogram (TTE) in pregnant women with methamphetamine use.
Trial opening soon.
Get Notified18 year–65 year
Female
Observational
This is a pilot study that examines previously undiagnosed cardiac pathology utilizing transthoracic echocardiogram (TTE) in pregnant women with chronic methamphetamine use and assesses possible screening modalities (cardiac point-of-care ultrasound (POCUS), serum biomarkers, electrocardiogram (EKG)) in identifying underlying disease in this population. As this is a prospective observational study, we will assess pregnancy-related complications and care connections in the pilot tertiary academic setting.
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
These criteria will exclude women whose medications, personal traits, obstetric conditions, or diseases could confound cardiovascular risk.
Time frame: Day 1
This outcome seeks to identify the sensitivity of point of care cardiac ultrasound for the identification of left ventricular systolic dysfunction in pregnant people who use methamphetamine when performed by an obstetrics provider, as compared to formal transthoracic echocardiogram.
Time frame: Day 1
This outcome seeks to identify the sensitivity of N-terminal pro-B-type natriuretic peptide (NT-proBNP), high sensitivity troponin and electrocardiogram for the identification of left ventricular systolic dysfunction in pregnant people who use methamphetamine, as compared to formal transthoracic echocardiogram.
Time frame: Day 1
This outcome seeks to identify the prevalence of structural heart disease in pregnant people who use methamphetamine.
Time frame: 3 months postpartum
This outcome seeks to identify the prevalence of pregnancy delivery complications in people who use methamphetamine.
Time frame: 3 months postpartum
This outcome seeks to identify linkage to cardiovascular and addiction specialty care among patients diagnosed with cardiovascular disease.
Contact information is provided by the study sponsor or research team.
Oregon Health and Science University
Other
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT05784467
Acquired Immunodeficiency Syndrome, Behavior
View Trial DetailsNCT06233799
Methamphetamine Abuse, Methamphetamine-dependence
Little Rock, Arkansas, United States
View Trial DetailsNCT04264741
Disease Attributes, Methamphetamine Abuse
Wuhan, China
View Trial DetailsNCT06721494
Methamphetamine Abuse, Methamphetamine Disorders
Glendale, California, United States
View Trial Details